Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual ...

An expert emphasizes that treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) are highly ...

An expert highlights that safety considerations in metastatic castration-resistant prostate cancer (mCRPC) treatment depend ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival ...

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma ...